Do analysts recommend VTVT or CGC?

vTv Therapeutics currently has a consensus target price of $55.83, indicating a potential upside of 67.87%. Given vTv Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe vTv Therapeutics is more favorable than Canopy Growth. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score vTv Therapeutics 2 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.50 Canopy Growth 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20

Does the media refer more to VTVT or CGC?

In the previous week, Canopy Growth had 2 more articles in the media than vTv Therapeutics. MarketBeat recorded 5 mentions for Canopy Growth and 3 mentions for vTv Therapeutics. Canopy Growth's average media sentiment score of 0.91 beat vTv Therapeutics' score of 0.34 indicating that Canopy Growth is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment vTv Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Canopy Growth 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is AVIR or VTVT more profitable?

vTv Therapeutics' return on equity of -6.27% beat Atea Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Atea Pharmaceuticals N/A -64.25% -57.12% vTv Therapeutics N/A -6.27% -5.06%

Does the media favor AVIR or VTVT?

In the previous week, vTv Therapeutics had 2 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 3 mentions for vTv Therapeutics and 1 mentions for Atea Pharmaceuticals. vTv Therapeutics' average media sentiment score of 0.34 beat Atea Pharmaceuticals' score of 0.00 indicating that vTv Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral vTv Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ENTA or VTVT?

In the previous week, Enanta Pharmaceuticals had 1 more articles in the media than vTv Therapeutics. MarketBeat recorded 4 mentions for Enanta Pharmaceuticals and 3 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 0.34 beat Enanta Pharmaceuticals' score of 0.21 indicating that vTv Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enanta Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral vTv Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is VTVT or PALI more profitable?

vTv Therapeutics' return on equity of -6.27% beat Palisade Bio's return on equity. Company Net Margins Return on Equity Return on Assets vTv Therapeutics N/A -6.27% -5.06% Palisade Bio N/A -33.47% -31.79%

Does the media refer more to VTVT or PALI?

In the previous week, Palisade Bio had 8 more articles in the media than vTv Therapeutics. MarketBeat recorded 11 mentions for Palisade Bio and 3 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 0.34 beat Palisade Bio's score of -0.21 indicating that vTv Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment vTv Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Palisade Bio 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

vTv Therapeutics (VTVT) Competitors

$33.26 +0.18 (+0.54%)

As of 08/21/2026 04:00 PM Eastern

Compare

VTVT vs. CGC, FENC, AVIR, ENTA, and PALI

Should you buy vTv Therapeutics stock or one of its competitors? vTv Therapeutics's main competitors and comparable companies include Canopy Growth (CGC), Adherex Technologies (FENC), Atea Pharmaceuticals (AVIR), Enanta Pharmaceuticals (ENTA), and Palisade Bio (PALI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does vTv Therapeutics compare to Canopy Growth?

vTv Therapeutics (NASDAQ:VTVT) and Canopy Growth (NASDAQ:CGC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

vTv Therapeutics has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market. Comparatively, Canopy Growth has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market.

vTv Therapeutics has a net margin of 0.00% compared to Canopy Growth's net margin of -65.33%. vTv Therapeutics' return on equity of -6.27% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	-6.27%	-5.06%
Canopy Growth	-65.33%	-21.91%	-14.34%

In the previous week, Canopy Growth had 2 more articles in the media than vTv Therapeutics. MarketBeat recorded 5 mentions for Canopy Growth and 3 mentions for vTv Therapeutics. Canopy Growth's average media sentiment score of 0.91 beat vTv Therapeutics' score of 0.34 indicating that Canopy Growth is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
vTv Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Canopy Growth	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

vTv Therapeutics has higher earnings, but lower revenue than Canopy Growth. vTv Therapeutics is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$1.02M	128.47	-$26.97M	-$1.06	N/A
Canopy Growth	$251.01M	1.88	-$190.29M	-$0.45	N/A

17.5% of vTv Therapeutics shares are held by institutional investors. Comparatively, 3.3% of Canopy Growth shares are held by institutional investors. 6.0% of vTv Therapeutics shares are held by insiders. Comparatively, 0.4% of Canopy Growth shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

vTv Therapeutics currently has a consensus target price of $55.83, indicating a potential upside of 67.87%. Given vTv Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe vTv Therapeutics is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Canopy Growth	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

vTv Therapeutics beats Canopy Growth on 10 of the 16 factors compared between the two stocks.

How does vTv Therapeutics compare to Adherex Technologies?

vTv Therapeutics (NASDAQ:VTVT) and Adherex Technologies (NASDAQ:FENC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

vTv Therapeutics has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market. Comparatively, Adherex Technologies has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market.

17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are owned by institutional investors. 6.0% of vTv Therapeutics shares are owned by company insiders. Comparatively, 10.7% of Adherex Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

vTv Therapeutics currently has a consensus target price of $55.83, suggesting a potential upside of 67.87%. Adherex Technologies has a consensus target price of $17.00, suggesting a potential upside of 50.58%. Given vTv Therapeutics' higher possible upside, equities research analysts clearly believe vTv Therapeutics is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

vTv Therapeutics has a net margin of 0.00% compared to Adherex Technologies' net margin of -6.09%. Adherex Technologies' return on equity of -5.71% beat vTv Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	-6.27%	-5.06%
Adherex Technologies	-6.09%	-5.71%	-2.37%

Adherex Technologies has higher revenue and earnings than vTv Therapeutics. Adherex Technologies is trading at a lower price-to-earnings ratio than vTv Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$1.02M	128.47	-$26.97M	-$1.06	N/A
Adherex Technologies	$44.64M	8.87	-$9.74M	-$0.13	N/A

In the previous week, vTv Therapeutics had 3 more articles in the media than Adherex Technologies. MarketBeat recorded 3 mentions for vTv Therapeutics and 0 mentions for Adherex Technologies. vTv Therapeutics' average media sentiment score of 0.34 beat Adherex Technologies' score of 0.00 indicating that vTv Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
vTv Therapeutics	Neutral
Adherex Technologies	Neutral

Summary

Adherex Technologies beats vTv Therapeutics on 8 of the 15 factors compared between the two stocks.

How does vTv Therapeutics compare to Atea Pharmaceuticals?

Atea Pharmaceuticals (NASDAQ:AVIR) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Atea Pharmaceuticals presently has a consensus price target of $7.00, indicating a potential upside of 28.91%. vTv Therapeutics has a consensus price target of $55.83, indicating a potential upside of 67.87%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe vTv Therapeutics is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
vTv Therapeutics	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by insiders. Comparatively, 6.0% of vTv Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

vTv Therapeutics' return on equity of -6.27% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-64.25%	-57.12%
vTv Therapeutics	N/A	-6.27%	-5.06%

In the previous week, vTv Therapeutics had 2 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 3 mentions for vTv Therapeutics and 1 mentions for Atea Pharmaceuticals. vTv Therapeutics' average media sentiment score of 0.34 beat Atea Pharmaceuticals' score of 0.00 indicating that vTv Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atea Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
vTv Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

vTv Therapeutics has higher revenue and earnings than Atea Pharmaceuticals. vTv Therapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A
vTv Therapeutics	$1.02M	128.47	-$26.97M	-$1.06	N/A

Atea Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market.

Summary

vTv Therapeutics beats Atea Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does vTv Therapeutics compare to Enanta Pharmaceuticals?

Enanta Pharmaceuticals (NASDAQ:ENTA) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

vTv Therapeutics has lower revenue, but higher earnings than Enanta Pharmaceuticals. vTv Therapeutics is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.26M	6.01	-$81.89M	-$2.41	N/A
vTv Therapeutics	$1.02M	128.47	-$26.97M	-$1.06	N/A

Enanta Pharmaceuticals has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market.

vTv Therapeutics has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -96.89%. vTv Therapeutics' return on equity of -6.27% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-96.89%	-61.84%	-20.70%
vTv Therapeutics	N/A	-6.27%	-5.06%

Enanta Pharmaceuticals presently has a consensus target price of $19.50, suggesting a potential upside of 44.77%. vTv Therapeutics has a consensus target price of $55.83, suggesting a potential upside of 67.87%. Given vTv Therapeutics' higher possible upside, analysts plainly believe vTv Therapeutics is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
vTv Therapeutics	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Enanta Pharmaceuticals had 1 more articles in the media than vTv Therapeutics. MarketBeat recorded 4 mentions for Enanta Pharmaceuticals and 3 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 0.34 beat Enanta Pharmaceuticals' score of 0.21 indicating that vTv Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enanta Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
vTv Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by company insiders. Comparatively, 6.0% of vTv Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

vTv Therapeutics beats Enanta Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does vTv Therapeutics compare to Palisade Bio?

vTv Therapeutics (NASDAQ:VTVT) and Palisade Bio (NASDAQ:PALI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

vTv Therapeutics' return on equity of -6.27% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	-6.27%	-5.06%
Palisade Bio	N/A	-33.47%	-31.79%

In the previous week, Palisade Bio had 8 more articles in the media than vTv Therapeutics. MarketBeat recorded 11 mentions for Palisade Bio and 3 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 0.34 beat Palisade Bio's score of -0.21 indicating that vTv Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
vTv Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Palisade Bio	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Palisade Bio has lower revenue, but higher earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$1.02M	128.47	-$26.97M	-$1.06	N/A
Palisade Bio	$250K	1,463.87	-$16.78M	-$0.48	N/A

vTv Therapeutics presently has a consensus price target of $55.83, suggesting a potential upside of 67.87%. Palisade Bio has a consensus price target of $9.00, suggesting a potential upside of 328.57%. Given Palisade Bio's stronger consensus rating and higher probable upside, analysts plainly believe Palisade Bio is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

vTv Therapeutics has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market.

17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 11.8% of Palisade Bio shares are owned by institutional investors. 6.0% of vTv Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Palisade Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Palisade Bio beats vTv Therapeutics on 10 of the 16 factors compared between the two stocks.

Get vTv Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VTVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VTVT vs. The Competition

Export

Metric	vTv Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$130.99M	$12.54B	$7.37B	$12.85B
Dividend Yield	N/A	2.61%	2.53%	11.08%
P/E Ratio	-31.38	789.80	272.60	24.24
Price / Sales	128.47	764.50	618.96	99.81
Price / Cash	N/A	96.77	78.62	53.99
Price / Book	1.67	11.89	13.05	6.20
Net Income	-$26.97M	$2.81B	$3.47B	$348.59M
7 Day Performance	10.42%	1.77%	2.09%	0.08%
1 Month Performance	5.05%	3.85%	6.64%	3.88%
1 Year Performance	117.80%	6.56%	25.02%	16.98%

vTv Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VTVT vTv Therapeutics	3.1448 of 5 stars	$33.26 +0.5%	$55.83 +67.9%	+117.8%	$130.99M	$1.02M	N/A	9
CGC Canopy Growth	0.8963 of 5 stars	$0.99 -1.0%	N/A	-17.3%	$457.39M	$251.01M	N/A	1,128
FENC Adherex Technologies	3.2402 of 5 stars	$11.87 +0.3%	$17.00 +43.2%	+30.4%	$410.88M	$44.64M	N/A	10
AVIR Atea Pharmaceuticals	1.7659 of 5 stars	$5.28 +1.1%	$7.00 +32.6%	+48.4%	$410.65M	N/A	N/A	70	Positive News
ENTA Enanta Pharmaceuticals	1.6375 of 5 stars	$13.30 +3.7%	$19.50 +46.6%	+52.5%	$383.29M	$65.32M	N/A	160	News Coverage Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VTVT) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

vTv Therapeutics (VTVT) Competitors

VTVT vs. CGC, FENC, AVIR, ENTA, and PALI

How does vTv Therapeutics compare to Canopy Growth?

Summary

How does vTv Therapeutics compare to Adherex Technologies?

Summary

How does vTv Therapeutics compare to Atea Pharmaceuticals?

Summary

How does vTv Therapeutics compare to Enanta Pharmaceuticals?

Summary

How does vTv Therapeutics compare to Palisade Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTVT vs. The Competition

vTv Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

vTv Therapeutics (VTVT) Competitors

VTVT vs. CGC, FENC, AVIR, ENTA, and PALI

How does vTv Therapeutics compare to Canopy Growth?

Which has more volatility & risk, VTVT or CGC?

Is VTVT or CGC more profitable?

Does the media refer more to VTVT or CGC?

Which has higher earnings and valuation, VTVT or CGC?

Do institutionals and insiders believe in VTVT or CGC?

Do analysts recommend VTVT or CGC?

Summary

How does vTv Therapeutics compare to Adherex Technologies?

Which has more volatility & risk, VTVT or FENC?

Do insiders & institutionals have more ownership in VTVT or FENC?

Do analysts rate VTVT or FENC?

Is VTVT or FENC more profitable?

Which has better earnings and valuation, VTVT or FENC?

Does the media prefer VTVT or FENC?

Summary

How does vTv Therapeutics compare to Atea Pharmaceuticals?

Do analysts recommend AVIR or VTVT?

Do institutionals and insiders believe in AVIR or VTVT?

Is AVIR or VTVT more profitable?

Does the media favor AVIR or VTVT?

Which has higher valuation and earnings, AVIR or VTVT?

Which has more risk & volatility, AVIR or VTVT?

Summary

How does vTv Therapeutics compare to Enanta Pharmaceuticals?

Which has preferable valuation & earnings, ENTA or VTVT?

Which has more risk & volatility, ENTA or VTVT?

Is ENTA or VTVT more profitable?

Do analysts rate ENTA or VTVT?

Does the media prefer ENTA or VTVT?

Do institutionals & insiders have more ownership in ENTA or VTVT?

Summary

How does vTv Therapeutics compare to Palisade Bio?

Is VTVT or PALI more profitable?

Does the media refer more to VTVT or PALI?

Which has higher valuation and earnings, VTVT or PALI?

Do analysts rate VTVT or PALI?

Which has more volatility & risk, VTVT or PALI?

Do insiders & institutionals hold more shares of VTVT or PALI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTVT vs. The Competition

vTv Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools